PDF herunterladen
Digestive Disease Interventions 2017; 01(01): 047-052
DOI: 10.1055/s-0037-1600117
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Locoregional Therapy for Cholangiocarcinoma

Nathan E. Frenk
1   Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Ronald S. Arellano
1   Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
› Institutsangaben
Weitere Informationen

Publikationsverlauf

06. Dezember 2016

03. Februar 2017

Publikationsdatum:
20. März 2017 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Cholangiocarcinoma represents the second most common primary hepatic malignancy and carries an overall poor prognosis. While surgical resection offers the only chances for cure, few patients are surgical candidates at the time of diagnosis. Chemotherapeutic treatment with gemcitabine and cisplatin is the standard chemotherapeutic regimen, but this offers only marginal overall survival benefits. With advances in minimally invasive techniques in the past decade, locoregional therapies with thermal ablation and transarterial techniques are increasingly being investigated as treatment options. This review explores emerging technologies and their potential role in treating cholangiocarcinoma.

Keywords

locoregional therapy - cholangiocarcinoma - intrahepatic cholangiocarcinoma - thermal ablation - transarterial chemoembolization - radioembolization
 

  • References

  • 1 Schmassmann A. Nonsurgical therapies for hepatocellular and cholangiocellular carcinoma. Swiss Surg 1999; 5 (3) 116-121
    CrossrefPubMedGoogle Scholar
  • 2 Scheuermann U, Kaths JM, Heise M , et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma—a single-center experience. Eur J Surg Oncol 2013; 39 (6) 593-600
    CrossrefPubMedGoogle Scholar
  • 3 Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol 2013; 29 (3) 324-328
    CrossrefPubMedGoogle Scholar
  • 4 Knüppel M, Kubicka S, Vogel A , et al. Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis. Gastroenterol Res Pract 2012; 2012: 190708
    PubMedGoogle Scholar
  • 5 Park HM, Yun SP, Lee EC , et al. Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol 2016; 23 (13) 4392-4400
    CrossrefPubMedGoogle Scholar
  • 6 Livraghi T, Meloni F, Di Stasi M , et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008; 47 (1) 82-89
    CrossrefPubMedGoogle Scholar
  • 7 Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg 2002; 68 (4) 395-397
    PubMedGoogle Scholar
  • 8 Zgodzinski W, Espat NJ. Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma. World J Gastroenterol 2005; 11 (33) 5239-5240
    PubMedGoogle Scholar
  • 9 Chiou YY, Hwang JI, Chou YH, Wang HK, Chiang JH, Chang CY. Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci 2005; 21 (7) 304-309
    CrossrefPubMedGoogle Scholar
  • 10 Giorgio A, Calisti G, DE Stefano G , et al. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience. Anticancer Res 2011; 31 (12) 4575-4580
    PubMedGoogle Scholar
  • 11 Butros SR, Shenoy-Bhangle A, Mueller PR, Arellano RS. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin Imaging 2014; 38 (4) 490-494
    CrossrefPubMedGoogle Scholar
  • 12 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am 2014; 23 (2) 383-397
    CrossrefPubMedGoogle Scholar
  • 13 Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg 2002; 89 (11) 1396-1401
    CrossrefPubMedGoogle Scholar
  • 14 Xu HX, Wang Y, Lu MD, Liu LN. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol 2012; 85 (1016): 1078-1084
    CrossrefPubMedGoogle Scholar
  • 15 Yu MA, Liang P, Yu XL , et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur J Radiol 2011; 80 (2) 548-552
    CrossrefPubMedGoogle Scholar
  • 16 Yang GW, Zhao Q, Qian S , et al. Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma. Onco Targets Ther 2015; 8: 1245-1250
    PubMedGoogle Scholar
  • 17 Hyder O, Hatzaras I, Sotiropoulos GC , et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013; 153 (6) 811-818
    CrossrefPubMedGoogle Scholar
  • 18 Herber S, Otto G, Schneider J , et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30 (6) 1156-1165
    CrossrefPubMedGoogle Scholar
  • 19 Shariff MI, Khan SA, Westaby D. The palliation of cholangiocarcinoma. Curr Opin Support Palliat Care 2013; 7 (2) 168-174
    CrossrefPubMedGoogle Scholar
  • 20 Seidensticker R, Seidensticker M, Doegen K , et al. extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract 2016; 2016: 8732521
    PubMedGoogle Scholar
  • 21 Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 2011; 66 (4) 322-328
    CrossrefPubMedGoogle Scholar
  • 22 Venturini M, Sallemi C, Agostini G , et al. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study. Br J Radiol 2016; 89 (1067): 20160247
    CrossrefPubMedGoogle Scholar
  • 23 Ray Jr CE, Edwards A, Smith MT , et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24 (8) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 24 Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40 (2) 105-121
    CrossrefPubMedGoogle Scholar
  • 25 Sharma B, Martin A, Zerizer I. Positron emission tomography-computed tomography in liver imaging. Semin Ultrasound CT MR 2013; 34 (1) 66-80
    CrossrefPubMedGoogle Scholar
  • 26 Camacho JC, Kokabi N, Xing M, Schuster DM, Kim HS. PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90 yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma. Clin Nucl Med 2014; 39 (11) 944-950
    CrossrefPubMedGoogle Scholar
  • 27 Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol 2015; 42 (1) 59-64
    CrossrefPubMedGoogle Scholar
  • 28 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17 (2) 484-491
    CrossrefPubMedGoogle Scholar
  • 29 Mouli S, Memon K, Baker T , et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013; 24 (8) 1227-1234
    CrossrefPubMedGoogle Scholar
  • 30 Kloeckner R, Ruckes C, Kronfeld K , et al. Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials 2014; 15: 311
    CrossrefPubMedGoogle Scholar
  • 31 Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J Gastroenterol 2015; 21 (27) 8271-8283
    CrossrefPubMedGoogle Scholar
  • 32 Mosconi C, Gramenzi A, Ascanio S , et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer 2016; 115 (3) 297-302
    CrossrefPubMedGoogle Scholar
  • 33 Soydal C, Kucuk ON, Bilgic S, Ibis E. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med 2016; 30 (1) 29-34
    CrossrefPubMedGoogle Scholar
  • 34 Rayar M, Sulpice L, Edeline J , et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 2015; 22 (9) 3102-3108
    CrossrefPubMedGoogle Scholar
  • 35 Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41 (1) 120-127
    CrossrefPubMedGoogle Scholar